Article(id=1330228335084417270, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228319234142315, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.08.003, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1641916800000, receivedDateStr=2022-01-12, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795080749530, onlineDateStr=2026-11-19, pubDate=1660060800000, pubDateStr=2022-08-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795080749530, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795080749530, creator=13701087609, updateTime=1795080749530, updator=13701087609, issue=Issue{id=1330228319234142315, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='8', pageStart='961', pageEnd='1066', issueExtLink='null', onlineDate='null', pubDate='1660060800000', pubDateStr='2022-08-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795080745752, creator='13701087609', updateTime=1795084770606, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330245201056084694, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228319234142315, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330245201056084695, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228319234142315, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=975, endPage=981, ext={EN=ArticleExt(id=1330228335310909687, articleId=1330228335084417270, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=The treatment progress on immune checkpoint inhibitors in children with malignant hematological diseases and tumors, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Programmed cell death protein-1 (PD-1)/programmed cell death 1 ligand-1 (PD-L1) inhibitors have certain antitumor activity on children with recurrent or refractory Hodgkin lymphoma (HL), recurrent or refractory primary mediastinal large B-cell lymphoma, unresectable or metastatic microsatellite instability-high or deficient mismatch repair solid tumor with progression after treatment, recurrent or metastatic Merkel cell carcinoma, especially in children with recurrent or refractory HL. Insufficient expression of PD-1 and PD-L1 can be used as biomarkers to select children who may respond to PD-1/PD-L1 inhibitors. Cytotoxic T lymphocyte antigen-4 inhibitors can be used for the treatment of patients aged 12 and over with unresectable tumors and metastatic melanoma. Immune checkpoint inhibitors (ICIs) are relatively safe and well tolerated. The combined application of multiple ICIs, combined with chemotherapeutic drugs, DNA methyltransferase inhibitors, CD30 antibodies and chimeric antigen receptor T-cell immunotherapy may further improve the curative effect. This article reviewed the research progress of ICIs in the treatment of pediatric hematologic malignancies and tumors in recent years, in order to provide some reference for clinical diagnosis and treatment.

, authors=Xiaohong QIAO, authorsList=Xiaohong QIAO, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330228337135431929, articleId=1330228335084417270, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=免疫检查点抑制剂在儿童恶性血液病及肿瘤治疗中的研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

程序性死亡受体1(programmed cell death protein-1,PD-1)/程序性死亡-配体1(programmed cell death 1 ligand-1,PD-L1)抑制剂部分剂型对儿童复发/难治性霍奇金淋巴瘤(Hodgkin lymphoma,HL)、复发/难治性原发纵隔大B细胞淋巴瘤、不可切除或转移性高度微卫星不稳定型、治疗后进展的错配修复功能缺陷型实体瘤、复发/转移性Merkel细胞癌等均有一定抗肿瘤活性,尤其在复发/难治性HL患儿的治疗中表现出较佳的抗肿瘤活性。PD-1及PD-L1的表达不足以作为选择可能对PD-1/PD-L1抑制剂有反应的患儿的生物标志物。细胞毒性T淋巴细胞相关蛋白4抑制剂部分剂型可用于对不可切除肿瘤及转移性黑色素瘤的12岁及以上患者的治疗。免疫检查点抑制剂(immune checkpoint inhibitor,ICI)具有相对良好的安全性及耐受性。多种ICI的联用,及其联合化疗药物、DNA甲基转移酶抑制剂、CD30抗体、嵌合抗原受体T细胞治疗等的综合运用或可进一步提高疗效。现就近年来ICI在儿童恶性血液病及肿瘤治疗中的研究进展作一综述,旨在为临床诊治提供一定参考。

, authors=乔晓红, authorsList=乔晓红, authorCompany=null, correspAuthors=null, authorNote=

乔晓红,博士生导师,副教授,研究方向:儿童血液肿瘤疾病、慢性咳嗽、反复呼吸道感染、小儿性早熟及矮小症。

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=K72LcuWR76soXbYTq+kLBQ==, magXml=J2YWEqGEWrTqyT9mE9kjQw==, pdfUrl=null, pdf=LDgC/hMojnVuUOGA5pSp+w==, pdfFileSize=1637757, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=JX+r7dm0gA70zs5Oz/hGrw==, mapNumber=null, fund=null)}, authors=[Author(id=1330228337454199038, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228337529696512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, authorId=1330228337454199038, language=EN, stringName=Xiaohong QIAO, firstName=Xiaohong, middleName=null, lastName=QIAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pediatrics, Tongji Hospital of Tongji University, Shanghai 200065, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228337613582594, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, authorId=1330228337454199038, language=CN, stringName=乔晓红, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海市同济医院,同济大学附属同济医院儿科,上海 200065, bio={"content":"

乔晓红,博士生导师,副教授,研究方向:儿童血液肿瘤疾病、慢性咳嗽、反复呼吸道感染、小儿性早熟及矮小症。

"}, bioImg=null, bioContent=

乔晓红,博士生导师,副教授,研究方向:儿童血液肿瘤疾病、慢性咳嗽、反复呼吸道感染、小儿性早熟及矮小症。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228337349341434, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, xref=null, ext=[AuthorCompanyExt(id=1330228337357730043, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, companyId=1330228337349341434, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatrics, Tongji Hospital of Tongji University, Shanghai 200065, China), AuthorCompanyExt(id=1330228337370312956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, companyId=1330228337349341434, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海市同济医院,同济大学附属同济医院儿科,上海 200065)])])], keywords=[Keyword(id=1330228337705857283, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, language=EN, orderNo=1, keyword=immune checkpoint inhibitor), Keyword(id=1330228337760383236, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, language=EN, orderNo=2, keyword=children), Keyword(id=1330228337819103493, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, language=EN, orderNo=3, keyword=hematopathy), Keyword(id=1330228337894600966, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, language=EN, orderNo=4, keyword=tumor), Keyword(id=1330228337957515527, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, language=CN, orderNo=1, keyword=免疫检查点抑制剂), Keyword(id=1330228338024624392, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, language=CN, orderNo=2, keyword=儿童), Keyword(id=1330228338083344649, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, language=CN, orderNo=3, keyword=血液病), Keyword(id=1330228338142064906, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, language=CN, orderNo=4, keyword=肿瘤)], refs=[Reference(id=1330228338221756683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Vakkila J, Jaffe R, Michelow M, et al. Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors[J]. Clin Cancer Res, 2006, 12(7 Pt 1): 2049-2054., articleTitle=null, refAbstract=null), Reference(id=1330228338276282636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Park JA, Cheung NKV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies[J]. Cancer Treat Rev, 2017, 58: 22-33., articleTitle=null, refAbstract=null), Reference(id=1330228338326614285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Food and Drug Administration (FDA). Keytruda. (Pembrolizumab) For injection, for intravenous use[EB/OL]. (2019-11-18) [2021-05-25]. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228338385334542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Food and Drug Administration (FDA). Keytruda. MedWatch: The FDA safety information and adverse event reporting program[EB/OL]. (2021-01-02) [2021-05-25]. https://www.fda.gov/medwatch., articleTitle=null, refAbstract=null), Reference(id=1330228338452443407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Davis KL, Fox E, Reid JM, et al. ADVL1412: initial results of a phase Ⅰ/Ⅱ study of nivolumab and ipilimumab in pediatric patients with replased/refractory solid tumors: a COG study[J]. J Clin Oncol, 2017, 35: 10526., articleTitle=null, refAbstract=null), Reference(id=1330228338511163664, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Geoerger B, Zwaan CM, Marshall LV, et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study[J]. Lancet Oncol, 2020, 21(1): 134-144., articleTitle=null, refAbstract=null), Reference(id=1330228338569883921, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial[J]. Lancet Oncol, 2020, 21(4): 541-550., articleTitle=null, refAbstract=null), Reference(id=1330228338641187090, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=MarjaŃska A, Drogosiewicz M, Dembowska-BagiŃska B, et al. Nivolumab for the treatment of advanced pediatric malignancies[J]. Anticancer Res, 2020, 40(12): 7095-7100., articleTitle=null, refAbstract=null), Reference(id=1330228338716684563, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial[J]. Lancet Oncol, 2020, 21(1): 121-133., articleTitle=null, refAbstract=null), Reference(id=1330228338792182036, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Dilly-Feldis M, Aladjidi N, Refait JK, et al. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas[J]. Pediatr Blood Cancer, 2019, 66(5): e27571., articleTitle=null, refAbstract=null), Reference(id=1330228338850902293, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhou QH, Li KW, Chen X, et al. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma[J]. J Immunother Cancer, 2020, 8(1): e000157., articleTitle=null, refAbstract=null), Reference(id=1330228338926399766, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang XW, Bi XW, Liu PP, et al. Expression of PD-L1 on monocytes is a novel predictor of prognosis in natural Killer/T-cell lymphoma[J]. Front Oncol, 2020, 10: 1360., articleTitle=null, refAbstract=null), Reference(id=1330228338993508631, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=He HX, Gao Y, Fu JC, et al. VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma[J]. Oncoimmunology, 2021, 10(1): 1907059., articleTitle=null, refAbstract=null), Reference(id=1330228339064811800, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Pinto NR, Park JR, Murphy E, et al. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors[J]. Pediatr Blood Cancer, 2017, 64(11): e26613., articleTitle=null, refAbstract=null), Reference(id=1330228339140309273, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy[J]. Mol Cancer Ther, 2015, 14(4): 847-856., articleTitle=null, refAbstract=null), Reference(id=1330228339211612442, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Harker-Murray P, Leblanc T, Mascarin M, et al. Response-adapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and young adults with standard-risk relapsed/refractory classical Hodgkin lymphoma[J]. Blood, 2018, 132: 927., articleTitle=null, refAbstract=null), Reference(id=1330228339282915611, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Merchant MS, Wright M, Baird K, et al. Phase Ⅰ clinical trial of ipilimumab in pediatric patients with advanced solid tumors[J]. Clin Cancer Res, 2016, 22(6): 1364-1370., articleTitle=null, refAbstract=null), Reference(id=1330228339350024476, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Geoerger B, Bergeron C, Gore L, et al. Phase Ⅱ study of ipilimumab in adolescents with unresectable stage Ⅲ or Ⅳ malignant melanoma[J]. Eur J Cancer, 2017, 86: 358-363., articleTitle=null, refAbstract=null), Reference(id=1330228339421327645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 255., articleTitle=null, refAbstract=null), Reference(id=1330228339492630814, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Bristol-Myers Squibb. YERVOY®(ipilimumab) injection, for intravenous use[EB/OL]. (2019-11-18) [2021-07-25]. https://packageinserts.bms.com/pi/pi_yervoy.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228339563933983, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase Ⅲ trial[J]. J Clin Oncol, 2015, 33(10): 1191-1196., articleTitle=null, refAbstract=null), Reference(id=1330228339622654240, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Broglie L, Gershan J, Burke MJ. Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia[J]. Int J Hematol Oncol, 2019, 8(1): IJH10., articleTitle=null, refAbstract=null), Reference(id=1330228339702346017, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Tragiannidis A, Kyriakidis I, Zündorf I, et al. Invasive fungal infections in pediatric patients treated with tumor necrosis α(TNF-α) inhibitors[J]. Mycoses, 2017, 60(4): 222-229., articleTitle=null, refAbstract=null), Reference(id=1330228341321347362, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhao B, Zhao H, Zhao JX. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: nivolumab-related serious/fatal adverse events[J]. J Immunother Cancer, 2018, 6(1): 101., articleTitle=null, refAbstract=null), Reference(id=1330228341409427747, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Schwarz M, Kocher F, Niedersuess-Beke D, et al. Immunosuppression for immune checkpoint-related toxicity can cause Pneumocystis jirovecii pneumonia (PJP) in non-small-cell lung cancer (NSCLC): a report of 2 cases[J]. Clin Lung Cancer, 2019, 20(3): e247-e250., articleTitle=null, refAbstract=null), Reference(id=1330228341476536612, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Si S, Erickson K, Evageliou N, et al. An usual presentation of Pneumocystis jirovecii pneumonia in a woman treated with immune checkpoint inhibitor[J]. J Pediatr Hematol Oncol, 2021, 43(2): e163-e164., articleTitle=null, refAbstract=null), Reference(id=1330228341573005605, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Campbell BB, Light N, Fabrizio D, et al. Comprehensive analysis of hypermutation in human cancer[J]. Cell, 2017, 171(5): 1042-1056., articleTitle=null, refAbstract=null), Reference(id=1330228341640114470, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Lu C, Zhang JH, Nagahawatte P, et al. The genomic landscape of childhood and adolescent melanoma[J]. J Invest Dermatol, 2015, 135(3): 816-823., articleTitle=null, refAbstract=null), Reference(id=1330228341728194855, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371): 91-97., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1330228337349341434, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, xref=null, ext=[AuthorCompanyExt(id=1330228337357730043, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, companyId=1330228337349341434, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatrics, Tongji Hospital of Tongji University, Shanghai 200065, China), AuthorCompanyExt(id=1330228337370312956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, companyId=1330228337349341434, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海市同济医院,同济大学附属同济医院儿科,上海 200065)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.08.003, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.08.003, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.08.003, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.08.003, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1660060800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
免疫检查点抑制剂在儿童恶性血液病及肿瘤治疗中的研究进展
乔晓红
世界临床药物 | 医药专论 2022,43(8): 975-981
收起
收藏切换
世界临床药物 |医药专论 2022 , 43 (8) : 975 -981
免疫检查点抑制剂在儿童恶性血液病及肿瘤治疗中的研究进展
全屏
[Author(id=1330228337454199038, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228337529696512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, authorId=1330228337454199038, language=EN, stringName=Xiaohong QIAO, firstName=Xiaohong, middleName=null, lastName=QIAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pediatrics, Tongji Hospital of Tongji University, Shanghai 200065, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228337613582594, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, authorId=1330228337454199038, language=CN, stringName=乔晓红, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海市同济医院,同济大学附属同济医院儿科,上海 200065, bio={"content":"

乔晓红,博士生导师,副教授,研究方向:儿童血液肿瘤疾病、慢性咳嗽、反复呼吸道感染、小儿性早熟及矮小症。

"}, bioImg=null, bioContent=

乔晓红,博士生导师,副教授,研究方向:儿童血液肿瘤疾病、慢性咳嗽、反复呼吸道感染、小儿性早熟及矮小症。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228337349341434, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, xref=null, ext=[AuthorCompanyExt(id=1330228337357730043, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, companyId=1330228337349341434, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatrics, Tongji Hospital of Tongji University, Shanghai 200065, China), AuthorCompanyExt(id=1330228337370312956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228335084417270, companyId=1330228337349341434, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海市同济医院,同济大学附属同济医院儿科,上海 200065)])])]
乔晓红
作者信息
  • 上海市同济医院,同济大学附属同济医院儿科,上海 200065
作者简介:

乔晓红,博士生导师,副教授,研究方向:儿童血液肿瘤疾病、慢性咳嗽、反复呼吸道感染、小儿性早熟及矮小症。

The treatment progress on immune checkpoint inhibitors in children with malignant hematological diseases and tumors
Xiaohong QIAO
Affiliations
  • Department of Pediatrics, Tongji Hospital of Tongji University, Shanghai 200065, China
出版时间: 2022-08-10 doi: 10.13683/j.wph.2022.08.003
文章导航
收藏切换

程序性死亡受体1(programmed cell death protein-1,PD-1)/程序性死亡-配体1(programmed cell death 1 ligand-1,PD-L1)抑制剂部分剂型对儿童复发/难治性霍奇金淋巴瘤(Hodgkin lymphoma,HL)、复发/难治性原发纵隔大B细胞淋巴瘤、不可切除或转移性高度微卫星不稳定型、治疗后进展的错配修复功能缺陷型实体瘤、复发/转移性Merkel细胞癌等均有一定抗肿瘤活性,尤其在复发/难治性HL患儿的治疗中表现出较佳的抗肿瘤活性。PD-1及PD-L1的表达不足以作为选择可能对PD-1/PD-L1抑制剂有反应的患儿的生物标志物。细胞毒性T淋巴细胞相关蛋白4抑制剂部分剂型可用于对不可切除肿瘤及转移性黑色素瘤的12岁及以上患者的治疗。免疫检查点抑制剂(immune checkpoint inhibitor,ICI)具有相对良好的安全性及耐受性。多种ICI的联用,及其联合化疗药物、DNA甲基转移酶抑制剂、CD30抗体、嵌合抗原受体T细胞治疗等的综合运用或可进一步提高疗效。现就近年来ICI在儿童恶性血液病及肿瘤治疗中的研究进展作一综述,旨在为临床诊治提供一定参考。

免疫检查点抑制剂  /  儿童  /  血液病  /  肿瘤

Programmed cell death protein-1 (PD-1)/programmed cell death 1 ligand-1 (PD-L1) inhibitors have certain antitumor activity on children with recurrent or refractory Hodgkin lymphoma (HL), recurrent or refractory primary mediastinal large B-cell lymphoma, unresectable or metastatic microsatellite instability-high or deficient mismatch repair solid tumor with progression after treatment, recurrent or metastatic Merkel cell carcinoma, especially in children with recurrent or refractory HL. Insufficient expression of PD-1 and PD-L1 can be used as biomarkers to select children who may respond to PD-1/PD-L1 inhibitors. Cytotoxic T lymphocyte antigen-4 inhibitors can be used for the treatment of patients aged 12 and over with unresectable tumors and metastatic melanoma. Immune checkpoint inhibitors (ICIs) are relatively safe and well tolerated. The combined application of multiple ICIs, combined with chemotherapeutic drugs, DNA methyltransferase inhibitors, CD30 antibodies and chimeric antigen receptor T-cell immunotherapy may further improve the curative effect. This article reviewed the research progress of ICIs in the treatment of pediatric hematologic malignancies and tumors in recent years, in order to provide some reference for clinical diagnosis and treatment.

immune checkpoint inhibitor  /  children  /  hematopathy  /  tumor
乔晓红. 免疫检查点抑制剂在儿童恶性血液病及肿瘤治疗中的研究进展. 世界临床药物, 2022 , 43 (8) : 975 -981 . DOI: 10.13683/j.wph.2022.08.003
Xiaohong QIAO. The treatment progress on immune checkpoint inhibitors in children with malignant hematological diseases and tumors[J]. World Clinical Drug, 2022 , 43 (8) : 975 -981 . DOI: 10.13683/j.wph.2022.08.003

参考文献 引证文献
排序方式:
[1]
Vakkila J, Jaffe R, Michelow M, et al. Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors[J]. Clin Cancer Res, 2006, 12(7 Pt 1): 2049-2054.
[2]
Park JA, Cheung NKV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies[J]. Cancer Treat Rev, 2017, 58: 22-33.
[3]
Food and Drug Administration (FDA). Keytruda. (Pembrolizumab) For injection, for intravenous use[EB/OL]. (2019-11-18) [2021-05-25]. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
[4]
Food and Drug Administration (FDA). Keytruda. MedWatch: The FDA safety information and adverse event reporting program[EB/OL]. (2021-01-02) [2021-05-25]. https://www.fda.gov/medwatch.
[5]
Davis KL, Fox E, Reid JM, et al. ADVL1412: initial results of a phase Ⅰ/Ⅱ study of nivolumab and ipilimumab in pediatric patients with replased/refractory solid tumors: a COG study[J]. J Clin Oncol, 2017, 35: 10526.
[6]
Geoerger B, Zwaan CM, Marshall LV, et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study[J]. Lancet Oncol, 2020, 21(1): 134-144.
[7]
Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial[J]. Lancet Oncol, 2020, 21(4): 541-550.
[8]
MarjaŃska A, Drogosiewicz M, Dembowska-BagiŃska B, et al. Nivolumab for the treatment of advanced pediatric malignancies[J]. Anticancer Res, 2020, 40(12): 7095-7100.
[9]
Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial[J]. Lancet Oncol, 2020, 21(1): 121-133.
[10]
Dilly-Feldis M, Aladjidi N, Refait JK, et al. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas[J]. Pediatr Blood Cancer, 2019, 66(5): e27571.
[11]
Zhou QH, Li KW, Chen X, et al. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma[J]. J Immunother Cancer, 2020, 8(1): e000157.
[12]
Zhang XW, Bi XW, Liu PP, et al. Expression of PD-L1 on monocytes is a novel predictor of prognosis in natural Killer/T-cell lymphoma[J]. Front Oncol, 2020, 10: 1360.
[13]
He HX, Gao Y, Fu JC, et al. VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma[J]. Oncoimmunology, 2021, 10(1): 1907059.
[14]
Pinto NR, Park JR, Murphy E, et al. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors[J]. Pediatr Blood Cancer, 2017, 64(11): e26613.
[15]
Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy[J]. Mol Cancer Ther, 2015, 14(4): 847-856.
[16]
Harker-Murray P, Leblanc T, Mascarin M, et al. Response-adapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and young adults with standard-risk relapsed/refractory classical Hodgkin lymphoma[J]. Blood, 2018, 132: 927.
[17]
Merchant MS, Wright M, Baird K, et al. Phase Ⅰ clinical trial of ipilimumab in pediatric patients with advanced solid tumors[J]. Clin Cancer Res, 2016, 22(6): 1364-1370.
[18]
Geoerger B, Bergeron C, Gore L, et al. Phase Ⅱ study of ipilimumab in adolescents with unresectable stage Ⅲ or Ⅳ malignant melanoma[J]. Eur J Cancer, 2017, 86: 358-363.
[19]
Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 255.
[20]
Bristol-Myers Squibb. YERVOY®(ipilimumab) injection, for intravenous use[EB/OL]. (2019-11-18) [2021-07-25]. https://packageinserts.bms.com/pi/pi_yervoy.pdf.
[21]
Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase Ⅲ trial[J]. J Clin Oncol, 2015, 33(10): 1191-1196.
[22]
Broglie L, Gershan J, Burke MJ. Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia[J]. Int J Hematol Oncol, 2019, 8(1): IJH10.
[23]
Tragiannidis A, Kyriakidis I, Zündorf I, et al. Invasive fungal infections in pediatric patients treated with tumor necrosis α(TNF-α) inhibitors[J]. Mycoses, 2017, 60(4): 222-229.
[24]
Zhao B, Zhao H, Zhao JX. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: nivolumab-related serious/fatal adverse events[J]. J Immunother Cancer, 2018, 6(1): 101.
[25]
Schwarz M, Kocher F, Niedersuess-Beke D, et al. Immunosuppression for immune checkpoint-related toxicity can cause Pneumocystis jirovecii pneumonia (PJP) in non-small-cell lung cancer (NSCLC): a report of 2 cases[J]. Clin Lung Cancer, 2019, 20(3): e247-e250.
[26]
Si S, Erickson K, Evageliou N, et al. An usual presentation of Pneumocystis jirovecii pneumonia in a woman treated with immune checkpoint inhibitor[J]. J Pediatr Hematol Oncol, 2021, 43(2): e163-e164.
[27]
Campbell BB, Light N, Fabrizio D, et al. Comprehensive analysis of hypermutation in human cancer[J]. Cell, 2017, 171(5): 1042-1056.
[28]
Lu C, Zhang JH, Nagahawatte P, et al. The genomic landscape of childhood and adolescent melanoma[J]. J Invest Dermatol, 2015, 135(3): 816-823.
[29]
Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371): 91-97.
2022年第43卷第8期
10
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.08.003
  • 接收时间:2022-01-12
  • 首发时间:2026-11-19
  • 出版时间:2022-08-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-01-12
基金
作者信息
    上海市同济医院,同济大学附属同济医院儿科,上海 200065
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.08.003
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏